Novel cancer immunotherapy agents with survival benefit: recent successes and next steps, Nature Reviews Cancer, vol.208, issue.11, pp.805-817, 2011. ,
DOI : 10.1084/jem.20100619
URL : http://europepmc.org/articles/pmc3426440?pdf=render
CTLA-4 and PD-1 Pathways, American Journal of Clinical Oncology, vol.39, issue.1, pp.98-106, 2016. ,
DOI : 10.1097/COC.0000000000000239
URL : http://doi.org/10.1097/coc.0000000000000239
Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers, Archives of Pathology & Laboratory Medicine, vol.141, issue.6, pp.851-61, 2017. ,
DOI : 10.5858/arpa.2016-0361-RA
URL : http://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2016-0361-RA
Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non, Small Cell Lung Cancer. Sci Rep, vol.5, pp.13110-13115, 2015. ,
Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1, Clinical Cancer Research, vol.18, issue.24, pp.6580-6587, 2012. ,
DOI : 10.1158/1078-0432.CCR-12-1362
URL : http://clincancerres.aacrjournals.org/content/clincanres/18/24/6580.full.pdf
Pembrolizumab for the Treatment of Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.372, issue.21, pp.2018-2046, 2015. ,
DOI : 10.1056/NEJMoa1501824
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, New England Journal of Medicine, vol.373, issue.1, pp.23-34, 2015. ,
DOI : 10.1056/NEJMoa1504030
URL : http://www.zora.uzh.ch/id/eprint/113016/1/608_Larkin%20et%20al%20_NEJM%202015.pdf
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.373, issue.19, pp.1803-1816, 2015. ,
DOI : 10.1056/NEJMoa1510665
URL : http://europepmc.org/articles/pmc5719487?pdf=render
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial, The Lancet Oncology, vol.17, issue.7, pp.883-95, 2016. ,
DOI : 10.1016/S1470-2045(16)30098-5
URL : http://eprints.gla.ac.uk/118215/13/118215.pdf
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, The Lancet Oncology, vol.16, issue.4, pp.375-84, 2015. ,
DOI : 10.1016/S1470-2045(15)70076-8
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, New England Journal of Medicine, vol.373, issue.1, pp.23-34, 2015. ,
DOI : 10.1056/NEJMoa1504030
URL : http://www.zora.uzh.ch/id/eprint/113016/1/608_Larkin%20et%20al%20_NEJM%202015.pdf
Nivolumab versus Docetaxel in Advanced Nonsquamous Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.373, issue.17, pp.1627-1666, 2015. ,
DOI : 10.1056/NEJMoa1507643
URL : http://europepmc.org/articles/pmc5705936?pdf=render
Mutation, New England Journal of Medicine, vol.372, issue.4, pp.320-350, 2015. ,
DOI : 10.1056/NEJMoa1412082
URL : https://hal.archives-ouvertes.fr/hal-00699117
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.373, issue.2, pp.123-158, 2015. ,
DOI : 10.1056/NEJMoa1504627
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial, The Lancet Oncology, vol.17, issue.7, pp.883-95, 2016. ,
DOI : 10.1016/S1470-2045(16)30098-5
URL : http://eprints.gla.ac.uk/118215/13/118215.pdf
Pembrolizumab versus Ipilimumab in Advanced Melanoma, New England Journal of Medicine, vol.372, issue.26, pp.2521-2553, 2015. ,
DOI : 10.1056/NEJMoa1503093
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, The Lancet, vol.387, issue.10027, pp.1540-50, 2016. ,
DOI : 10.1016/S0140-6736(15)01281-7
, Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) -Full Text View -ClinicalTrials.gov n.d. https://clinicaltrials.gov/ct2/show, p.2252042, 2017.
Pembrolizumab versus Chemotherapy for PD-L1???Positive Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.375, issue.19, pp.1823-1856, 2016. ,
DOI : 10.1056/NEJMoa1606774
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, The Lancet, vol.387, issue.10030, pp.1837-1883, 2016. ,
DOI : 10.1016/S0140-6736(16)00587-0
IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC)., Journal of Clinical Oncology, vol.34, issue.2_suppl, pp.355-355, 2016. ,
DOI : 10.1200/jco.2016.34.2_suppl.355
PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis, Critical Reviews in Oncology/Hematology, vol.100, pp.88-98, 2016. ,
DOI : 10.1016/j.critrevonc.2016.02.001
The future of immune checkpoint therapy, Science, vol.19, issue.5, pp.56-61, 2015. ,
DOI : 10.1158/1078-0432.CCR-12-1630
Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study [abstract], J Clin Oncol, vol.31, pp.3001-3001, 2013. ,
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies, Annals of Oncology, vol.7, issue.1, pp.147-53, 2016. ,
DOI : 10.4103/0973-1482.163837
PD-L1 expression in advanced NSCLC: Primary lesions versus metastatic sites and impact of sample age [abstract] Diagnostic PD-L1 immunohistochemistry in NSCLC: Results of the first German harmonization study [abstract] Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma, J Clin Oncol J Clin Oncol Appl Immunohistochem Mol Morphol Bioconjug Chem, vol.343427, issue.15, pp.3025-3052, 2016. ,
Frequency of certain immune cells in blood may predict metastatic melanoma response to Pembrolizumab CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference ,
T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1, Release-Detail.aspx?ItemID=759 [31], pp.3800-3811, 2015. ,
DOI : 10.1158/0008-5472.CAN-15-1082
URL : http://cancerres.aacrjournals.org/content/canres/75/18/3800.full.pdf
Classifying Cancers Based on T-cell Infiltration and PD-L1, Cancer Research, vol.75, issue.11 ,
DOI : 10.1158/0008-5472.CAN-15-0255
URL : http://cancerres.aacrjournals.org/content/canres/75/11/2139.full.pdf
, Cancer Res, vol.75, pp.2139-2184, 2015.
PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.15, issue.7528, pp.568-71, 2014. ,
DOI : 10.1158/1078-0432.CCR-09-1624
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma, Clinical Cancer Research, vol.22, issue.22, pp.5461-71, 2016. ,
DOI : 10.1158/1078-0432.CCR-15-2839
Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma, Clinical Cancer Research, vol.23, issue.17, pp.5024-5057, 2017. ,
DOI : 10.1158/1078-0432.CCR-16-0698
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment, Journal of Translational Medicine, vol.10, issue.1, p.146, 2012. ,
DOI : 10.1002/eji.200939261
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10??mg/kg within an expanded access programme, Cancer Immunology, Immunotherapy, vol.91, issue.Suppl 7, pp.1021-1029, 2013. ,
DOI : 10.1002/jso.20329
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study, Annals of Oncology, vol.32, issue.5, pp.798-803, 2015. ,
DOI : 10.3109/07357907.2014.885984
Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy, Cancer Immunology Research, vol.1, issue.4, pp.229-263, 2013. ,
DOI : 10.1158/2326-6066.CIR-13-0020
Correlation of peripheral and intratumoral T-cell receptor (TCR) clonality with clinical outcomes in patients with metastatic urothelial cancer (mUC) treated with atezolizumab [abstract] Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis, J Clin Oncol PLoS Med, vol.3414, issue.15, pp.1002309-1002351, 2016. ,
T cells, EMBO Molecular Medicine, vol.185, issue.10, pp.581-92, 2011. ,
DOI : 10.4049/jimmunol.1001821
On the Mechanism of T cell receptor downmodulation and its physiological significance, The Journal of Bioscience and Medicine, vol.1, issue.1, 2011. ,
DOI : 10.5780/jbm2011.5
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma, Journal for ImmunoTherapy of Cancer, vol.19, issue.3, pp.23-45, 2015. ,
DOI : 10.1038/nm.3100
URL : https://jitc.biomedcentral.com/track/pdf/10.1186/s40425-015-0070-4?site=jitc.biomedcentral.com
CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire, Clinical Cancer Research, vol.20, issue.9, pp.2424-2456, 2014. ,
DOI : 10.1158/1078-0432.CCR-13-2648
URL : http://clincancerres.aacrjournals.org/content/clincanres/20/9/2424.full.pdf
Association between T cell repertoire diversification and both clinical response as well as toxicity following immune checkpoint blockade in metastatic cancer patients [abstract], J Clin Oncol, vol.3447, 2016. ,
DOI : 10.1158/1538-7445.am2016-4362
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients, British Journal of Cancer, vol.102, issue.12 ,
DOI : 10.1093/annonc/mdt161
URL : http://www.nature.com/bjc/journal/v112/n12/pdf/bjc2015180a.pdf
Early neutrophil to lymphocyte ratio dynamics to predict progression free survival in patients treated with immune-checkpoint inhibitors [abstract] Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy, Br J Cancer J Clin Oncol Oncotarget, vol.112347, pp.1904-1077404, 2015. ,
Association of eosinophila with efficacy in non-melanoma patients treated with programmed death 1 inhibitors [abstract], J Clin Oncol, vol.3451, 2016. ,
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival, Annals of Oncology, vol.62, issue.6, pp.1697-703, 2013. ,
DOI : 10.1111/j.1365-3083.2005.01682.x
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, New England Journal of Medicine, vol.372, issue.26, pp.2509-2529, 2015. ,
DOI : 10.1056/NEJMoa1500596
URL : http://europepmc.org/articles/pmc4481136?pdf=render
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma, New England Journal of Medicine, vol.371, issue.23, pp.2189-99, 2014. ,
DOI : 10.1056/NEJMoa1406498
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, vol.105, issue.51, pp.124-132, 2015. ,
DOI : 10.1073/pnas.0810114105
URL : http://europepmc.org/articles/pmc4993154?pdf=render
Mutational burden and activated T cell infiltration in lung squamous cell carcinomas with DNA repair mutations [abstract], J Clin Oncol, vol.3456, 2016. ,
Association of a specific innate immune response to DNA damage with DNA repair deficient colorectal cancers [abstract] Immune gene expression, survival outcome and response to PD-1/PD-L1 blockade: a TCGA pan-cancer analysis [abstract] Association of response to programmed death 1 receptor or ligand (PD1/PDL1) blockade with immune-related gene expression profiling across three cancer-types [abstract], J Clin Oncol J Clin Oncol J Clin Oncol, vol.3457343459, 2016. ,
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma, Cell, vol.165, issue.1, pp.35-44, 2016. ,
DOI : 10.1016/j.cell.2016.02.065
URL : https://doi.org/10.1016/j.cell.2016.02.065
Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy, Nature Genetics, vol.48, issue.11, pp.1327-1336, 2016. ,
DOI : 10.1007/s00251-015-0873-y
URL : http://europepmc.org/articles/pmc5553281?pdf=render
Could microbial therapy boost cancer immunotherapy?, Science, vol.368, issue.7, pp.1031-1033, 2015. ,
DOI : 10.1056/NEJMoa1205037
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy, Science, vol.68, issue.3, pp.1084-1093, 2015. ,
DOI : 10.1111/j.1574-6941.2009.00671.x
URL : http://europepmc.org/articles/pmc4873287?pdf=render
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota, Science, vol.17, issue.2, pp.1079-84, 2015. ,
DOI : 10.1016/j.anaerobe.2011.03.004
Positional scanningsynthetic peptide library-based analysis of self-and pathogen-derived peptide cross-reactivity with tumorreactive Melan-A-specific CTL, J Immunol Baltim Md, vol.65169, pp.5696-707, 1950. ,
DOI : 10.4049/jimmunol.169.10.5696
URL : http://www.jimmunol.org/content/jimmunol/169/10/5696.full.pdf
Infection, antibiotic therapy and risk of colorectal cancer: A nationwide nested case-control study in patients with Type 2 diabetes mellitus, International Journal of Cancer, vol.53, issue.4, pp.956-67, 2014. ,
DOI : 10.1093/cid/cir609
R??le du microbiote intestinal dans la r??ponse aux th??rapies anti-tumorales, Biologie Aujourd'hui, vol.8, issue.1, pp.51-67, 2017. ,
DOI : 10.1038/nri2216
TGF?? in Cancer, Cell, vol.134, issue.2, pp.215-245, 2008. ,
DOI : 10.1016/j.cell.2008.07.001
platform, Bioanalysis, vol.14, issue.23, pp.2415-2428, 2016. ,
DOI : 10.1186/s12014-015-9101-x
URL : https://hal.archives-ouvertes.fr/inria-00494120
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma, Journal of Translational Medicine, vol.9, issue.1, pp.204-71, 2011. ,
DOI : 10.1097/CJI.0b013e31817fd8f3
Indoleamine 2, 3-dioxygenase (IDO) is essential for dendritic cell activation and chemotactic responsiveness to chemokines, Cell Research, vol.196, issue.3, pp.167-75, 2005. ,
DOI : 10.1084/jem.20020052
Suppression of T-cell responses by tumor metabolites, Cancer Immunology, Immunotherapy, vol.10, issue.8, pp.425-456, 2011. ,
DOI : 10.1158/1078-0432.CCR-04-0039
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role, Transl Lung Cancer Res, vol.4, pp.728-770, 2015. ,